Analyzing Century Therapeutics (NASDAQ:IPSC) and Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH) and Century Therapeutics (NASDAQ:IPSC) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Volatility and Risk

Dianthus Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.

Valuation and Earnings

This table compares Dianthus Therapeutics and Century Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.90 million	2,340.28	-$162.34 million	($4.15)	-19.59
Century Therapeutics	$109.16 million	2.56	-$9.58 million	($0.93)	-1.66

Century Therapeutics has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dianthus Therapeutics and Century Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Century Therapeutics	N/A	-49.51%	-38.09%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Dianthus Therapeutics and Century Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1	0	13	2	3.00
Century Therapeutics	1	2	4	0	2.43

Dianthus Therapeutics presently has a consensus target price of $128.77, suggesting a potential upside of 58.36%. Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 207.44%. Given Century Therapeutics’ higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Dianthus Therapeutics.

Institutional & Insider Ownership

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Century Therapeutics beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.